Nicholas Investment Partners LP Increases Stake in United Therapeutics Corporation $UTHR

Nicholas Investment Partners LP lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 478.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,553 shares of the biotechnology company’s stock after acquiring an additional 3,766 shares during the period. Nicholas Investment Partners LP’s holdings in United Therapeutics were worth $2,218,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Focus Partners Wealth raised its holdings in shares of United Therapeutics by 138.8% during the 4th quarter. Focus Partners Wealth now owns 6,639 shares of the biotechnology company’s stock worth $3,235,000 after acquiring an additional 3,859 shares during the period. Fieldview Capital Management LLC purchased a new stake in United Therapeutics in the 4th quarter valued at about $527,000. Entropy Technologies LP raised its holdings in United Therapeutics by 61.7% in the 4th quarter. Entropy Technologies LP now owns 1,940 shares of the biotechnology company’s stock valued at $945,000 after buying an additional 740 shares during the period. Ariadne Wealth Management LP purchased a new stake in United Therapeutics in the 4th quarter valued at about $217,000. Finally, Aptus Capital Advisors LLC purchased a new stake in United Therapeutics in the 4th quarter valued at about $225,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $24,712,246.04. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $549.29, for a total value of $5,492,900.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,368,398.04. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 634,984 shares of company stock valued at $358,175,202. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Stock Up 0.1%

Shares of UTHR opened at $545.96 on Friday. The stock has a 50 day moving average price of $566.75 and a 200 day moving average price of $521.34. The company has a market capitalization of $23.17 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company posted $6.63 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on UTHR. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Royal Bank Of Canada dropped their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.